Efficacy and Safety of Tildrakizumab in the Treatment of Scalp Psoriasis
- Conditions
- First Posted Date
- 2019-04-01
- Last Posted Date
- 2023-05-31
- Lead Sponsor
- Sun Pharmaceutical Industries Limited
- Target Recruit Count
- 231
- Registration Number
- NCT03897088
- Locations
- 🇺🇸
SPARC Site 7, Fountain Valley, California, United States
🇺🇸SPARC Site 18, Encinitas, California, United States
🇺🇸SPARC Site 3, Fremont, California, United States
Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2019-04-01
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Sun Pharmaceutical Industries Limited
- Target Recruit Count
- 99
- Registration Number
- NCT03897075
- Locations
- 🇺🇸
California Dermatology & CRI (Site 18), Encinitas, California, United States
🇺🇸First OC Dermatology (Site 07), Fountain Valley, California, United States
🇺🇸Dermatology Research Associates (Site 09), Los Angeles, California, United States
A Real World Study Evaluating the Long-Term Quality of Life of Tildrakizumab in Adult Patients With Psoriasis
- First Posted Date
- 2018-10-24
- Last Posted Date
- 2023-02-23
- Lead Sponsor
- Sun Pharmaceutical Industries Limited
- Target Recruit Count
- 55
- Registration Number
- NCT03718299
- Locations
- 🇺🇸
Therapeutics Clinical Research, San Diego, California, United States
🇺🇸Site 02, Grandville, Michigan, United States
Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab.
- Conditions
- Interventions
- First Posted Date
- 2018-06-11
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Sun Pharmaceutical Industries Limited
- Target Recruit Count
- 281
- Registration Number
- NCT03552276
- Locations
- 🇺🇸
Site 25, Glendale, Arizona, United States
🇺🇸Site 16, Phoenix, Arizona, United States
🇺🇸Site 14, Denver, Colorado, United States
A Study to Evaluate the Effect of of Albuterol Sulfate Inhalation Aerosol, eq 90 mcg Base (Sun Pharmaceuticals Industries Limited)
- Conditions
- Interventions
- First Posted Date
- 2018-05-18
- Last Posted Date
- 2021-01-22
- Lead Sponsor
- Sun Pharmaceutical Industries Limited
- Target Recruit Count
- 128
- Registration Number
- NCT03528577
- Locations
- 🇺🇸
SPARC Site 04, Saint Louis, Missouri, United States
🇺🇸SPARC Site 02, Miami Lakes, Florida, United States
🇺🇸SPARC site 01, Bethesda, Maryland, United States
Multiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Treatment With Halobetasol Spray in Patients With Plaque Psoriasis
- First Posted Date
- 2017-10-02
- Last Posted Date
- 2021-06-14
- Lead Sponsor
- Sun Pharmaceutical Industries Limited
- Registration Number
- NCT03298581
Multiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Treatment With Halobetasol Spray in Patients With Atopic Dermatitis
- Conditions
- Interventions
- First Posted Date
- 2017-08-10
- Last Posted Date
- 2019-09-25
- Lead Sponsor
- Sun Pharmaceutical Industries Limited
- Target Recruit Count
- 20
- Registration Number
- NCT03245385
- Locations
- 🇺🇸
L&C Professional Medical Research Institute, Hazleton, Pennsylvania, United States
🇺🇸Millennium Clinical Research, INC, Miami, Florida, United States
🇺🇸Vista Health Research, Miami, Florida, United States
Evaluation of Adrenal Suppression Potential and Pharmacokinetics of Halobetasol Lotion 0.05%
- First Posted Date
- 2017-07-11
- Last Posted Date
- 2021-12-07
- Lead Sponsor
- Sun Pharmaceutical Industries Limited
- Target Recruit Count
- 16
- Registration Number
- NCT03212963
- Locations
- 🇺🇸
Power MD Clinical Research Institute, Hialeah, Florida, United States
🇺🇸MediSearch Clinical Trials, Saint Joseph, Missouri, United States
🇺🇸First OC Dermatology, Fountain Valley, California, United States
2nd Study to Assess ISV-305 Compared to Vehicle for Treatment of Inflammation and Pain Associated With Cataract Surgery
- Conditions
- Interventions
- First Posted Date
- 2017-06-19
- Last Posted Date
- 2021-11-19
- Lead Sponsor
- Sun Pharmaceutical Industries Limited
- Target Recruit Count
- 246
- Registration Number
- NCT03192150
- Locations
- 🇺🇸
Clinical Research Center, Austin, Texas, United States
Study to Evaluate ISV-305 Compared to Vehicle for Treatment of Inflammation and Pain Associated With Cataract Surgery
- Conditions
- Interventions
- First Posted Date
- 2017-06-19
- Last Posted Date
- 2021-11-19
- Lead Sponsor
- Sun Pharmaceutical Industries Limited
- Target Recruit Count
- 260
- Registration Number
- NCT03192137
- Locations
- 🇺🇸
Clinical Research Center, Memphis, Tennessee, United States